Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Test

InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Test

Nov 16, 2020
|
staff reporter

NEW YORK – InterVenn Biosciences announced Monday it has raised $34 million in a Series B financing round to commercialize its ovarian cancer diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

What's Popular?

In Business News

  1. Olink Files For Public Offering in US

  2. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  3. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  4. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  5. Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.